EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Updates in Cancer Cachexia: Clinical Management and Pharmacologic Interventions

Sudeep Pandey iD, Lauren Bradley, Egidio Del Fabbro

Cancers · 27.04.2024 · 16 (9) · 1696

DOI: 10.3390/cancers16091696 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.04.2024. Verfasst von Sudeep Pandey und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology, Oncology and Palliative Care, Virginia Commonwealth University, Richmond, VA 23298, USA. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite a better understanding of the mechanisms causing cancer cachexia (CC) and development of promising pharmacologic and supportive care interventions, CC persists as an underdiagnosed and undertreated condition. CC contributes to fatigue, poor quality of life, functional impairment, increases treatment related toxicity, and reduces survival. The core elements of CC such as weight loss and poor appetite should be identified early. Currently, addressing contributing conditions (hypothyroidism, hypogonadism, and adrenal insufficiency), managing nutrition impact symptoms leading to decreased oral intake (nausea, constipation, dysgeusia, stomatitis, mucositis, pain, fatigue, depressed mood, or anxiety), and the addition of pharmacologic agents when appropriate (progesterone analog, corticosteroids, and olanzapine) is recommended. In Japan, the clinical practice has changed based on the availability of Anamorelin, a ghrelin receptor agonist that improved lean body mass, weight, and appetite-related quality of life (QoL) compared to a placebo, in phase III trials. Other promising therapeutic agents currently in trials include Espindolol, a non-selective β blocker and a monoclonal antibody to GDF-15. In the future, a single therapeutic agent or perhaps multiple medications targeting the various mechanisms of CC may prove to be an effective strategy. Ideally, these medications should be incorporated into a multimodal interdisciplinary approach that includes exercise and nutrition.

Schlagwörter

Stichwörter der Autor:innen

cachexiacancercancer cachexiawasting syndrome

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Hematology, Oncology and Palliative Care, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Department of Medicine, Division of Palliative Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.

ORCID-Profile: Sudeep Pandey

Zitieren

APA

Pandey, S., Bradley, L., & Del Fabbro, E. (2024). Updates in Cancer Cachexia: Clinical Management and Pharmacologic Interventions. Cancers, 16(9), 1696. https://doi.org/10.3390/cancers16091696

Vancouver

Pandey S, Bradley L, Del Fabbro E. Updates in Cancer Cachexia: Clinical Management and Pharmacologic Interventions. Cancers. 2024;16(9):1696. doi:10.3390/cancers16091696

BibTeX
@article{Pandey2024,
  author = {Pandey, Sudeep and Bradley, Lauren and Del Fabbro, Egidio},
  title = {Updates in Cancer Cachexia: Clinical Management and Pharmacologic Interventions},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {9},
  pages = {1696},
  doi = {10.3390/cancers16091696}
}
Kostenlos starten →